Gen9 Ramps Up Commercial Leadership Team with Senior Sales and R&D Appointments

Gen9 Ramps Up Commercial Leadership Team with Senior Sales and R&D Appointments

Life science industry veterans bring nearly four decades of technology R&D and global sales expertise to pioneering gene synthesis company

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gen9, Inc., a pioneer in the development of scalable technologies for synthesizing and assembling DNA, today announced the appointment of Christopher Bruce, Vice President of Global Sales, and Devin Leake, Vice President of Research & Development. These additions underscore Gen9's commitment to expanding its global sales footprint and driving innovation in the high-throughput, automated production of DNA constructs at lower cost and higher accuracy.

"Gen9 is undergoing an exciting time of growth and I am delighted to welcome Chris and Devin to the team. Their experience and leadership will allow us to continue the rapid expansion of our operations and meet the strong global demand for our DNA constructs"
"Gen9 is undergoing an exciting time of growth and I am delighted to welcome Chris and Devin to the team. Their experience and leadership will allow us to continue the rapid expansion of our operations and meet the strong global demand for our DNA constructs," said Kevin Munnelly, CEO of Gen9. "Gen9 has created the capacity to produce custom DNA at a scale that is enabling virtually limitless opportunity in the use of biologically derived building blocks across the biomedical research, agricultural, pharmaceutical, chemical, biofuel, and even food and fragrance industries."

Bruce brings more than 25 years of sales and commercial leadership experience to Gen9. He joins the company from Cell Signaling Technology (CST) where he was most recently Sr. Director of Sales. In this role, he was responsible for developing the company's sales presence in the United States, and he facilitated the establishment of three international offices to expand CST's worldwide sales and marketing reach. Prior, Bruce worked for Invitrogen (Life Technologies), and Pierce (Thermo Fisher) as Director of Global Sales focused on developing sales strategy, sales channel management and distribution. He holds a B.S. in biological sciences from the State University of New York at Stony Brook.

Leake joins Gen9 from Thermo Fisher Scientific, where he was most recently Global Director of Molecular Biology R&D overseeing research in enzyme development and nucleic acid chemistry and biology. Before that, he worked at Dharmacon, an RNA synthesis company acquired by Thermo Fisher Scientific. Leake has more than 100 issued patents and over 30 publications in peer-reviewed journals. He holds a Ph.D. in molecular biology and biochemistry from the State University of New York at Stony Brook and a B.A. in molecular biology from the University of Texas at Austin.

Gen9 is a privately held gene synthesis and synthetic biology company with a rapidly growing portfolio of products. Currently, Gen9 is manufacturing and shipping double-stranded GeneBits® DNA constructs (up to 1,000 base pairs in length) and GeneBytes® DNA constructs (from 1,000 base pairs to 3,000 base pairs). Also, by the end of 2013, Gen9 will begin selling synthesized DNA constructs as long as 10Kb. All of Gen9's products are sequence verified and sent in clonal form, either in a vector or as linear DNA.

For more information, please visit www.Gen9Bio.com.

About Gen9

Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is based in Cambridge, Mass., and can be found online at www.gen9bio.com.

Gen9, GeneBits, and GeneBytes are trademarks or registered trademarks of Gen9, Inc. All other brands may be trademarks of their respective holders.

Contacts

for Gen9, Inc.
Colin Sanford, 203-340-2441
[email protected]

Suggested Articles

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.